Odronextamab’s Regulatory Journey Highlights Diverging EU and US Requirements

 
• By Manas Mishra
  
Traffic Sign With Diverging Roads
Regeneron's lymphoma product odronextamab was authorized in the EU just months after a US rejection in 2024, followed by a recent complete response letter this year. (Shutterstock)

More from Pathways & Standards

More from Pink Sheet